- Morgan Stanley upgrades Valeant Pharmaceuticals (VRX +1.9%) to Overweight from Equalweight.
- "Only 10% of pro forma 2013 estimated revenue is subject to patent cliffs and no more than 3% of revenue is at risk to generics annually in 2014-2017 estimates," analyst Christopher Caponetti says, adding that VRX is "one of the best positioned specialty pharmaceutical companies to capitalize on industry consolidation." Price target is $145.
- Also bullish is Aegis, where analyst Raghuram Selvaraju lifts the price target on the shares to $160 from $140, noting management's ambitious plan to "ascend to the ranks of the top five pharmaceutical firms in the world by the end of 2016."
- See also: VRX aims to be top-five pharmaceutical company
From other sites
at MarketRealist.com (Mar 27, 2015)
at Zacks.com (Mar 25, 2015)
at Zacks.com (Mar 24, 2015)
at MarketRealist.com (Mar 23, 2015)
at Zacks.com (Mar 23, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs